Author Archives: admin


Stem Cell Clinic > Articles by: admin

BeyondSpring Files 2021 Annual Report on Form 20-F

By Global News Feed

NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission (“SEC”) on April 14, 2022. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section.

Read the original post:
BeyondSpring Files 2021 Annual Report on Form 20-F

Immunicum AB: Immunicum to Participate in the New Cancer Research Consortium Oncode-PACT

By Global News Feed

Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced that the company will participate in the public-private partnership Oncode-PACT, which will be supported by the National Growth Fund, an initiative of the Dutch Ministry of Economic Affairs and Climate Policy and the Ministry of Finance.

Originally posted here:
Immunicum AB: Immunicum to Participate in the New Cancer Research Consortium Oncode-PACT

Virbac : Very strong growth in revenue in the first quarter of 2022 of +16.2% at comparable exchange rates (+19.3% at real rates), driven by good…

By Global News Feed

1 Growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the previous financial year), and excluding change in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year.

Read this article:
Virbac : Very strong growth in revenue in the first quarter of 2022 of +16.2% at comparable exchange rates (+19.3% at real rates), driven by good...

Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments

By Global News Feed

DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31

Read more:
Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments

Terranueva: Results of the Shareholders Meeting

By Global News Feed

L’ASSOMPTION, Quebec, April 14, 2022 (GLOBE NEWSWIRE) -- Terranueva Corporation (CSE: TEQ) ("Terranueva" or the "Company") is pleased to announce the results of its annual and special meeting of shareholders held on April 14, 2022. The shareholders approved, by a majority of votes, a resolution to elect the following directors: Sylvain Aird, Marc-André Aubé, Marianne Fortier-Landry, Gérard Landry, Jean-Luc Landry, Peter Polatos and Sylvain Tremblay. Also, the shareholders, by a majority of votes, proceeded with the appointment of PricewaterhouseCoopers LLP as auditors of the Corporation, as well as approved the Corporation’s Fixed Stock Option Plan in order to increase at 4,596,996 the maximum of common shares to be issued upon exercise of options, which represents 10% of the number of common share in the capital stock of Terranueva as of the record date of March 14, 2022.

See the original post:
Terranueva: Results of the Shareholders Meeting

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

By Global News Feed

IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that it will host its first R&D Day on Thursday, April 28, 2022, from 10 a.m. to 12 p.m. ET (7 a.m. to 9 a.m. PT). Members of Eledon’s senior management team will be joined by four leading experts for a deep dive on the company’s investigational drug, tegoprubart, and the promise of CD40 Ligand targeted immunotherapy for the treatment of amyotrophic lateral sclerosis, kidney transplantation, islet cell transplantation, and IgA nephropathy.

Visit link:
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

Angion Announces Participation in Upcoming Investment Conference

By Global News Feed

UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.

Read more from the original source:
Angion Announces Participation in Upcoming Investment Conference

→←